Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

May 31, 2014

Conditions
Pain
Interventions
DRUG

Oxycodone hydrochloride controlled-release tablets

Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.

Trial Locations (14)

10016

New York University Langone Medical Center, New York

11794

Stony Brook University Hospital, Stony Brook

28204

Presbyterian Blume Pediatric Hematology & Oncology Clinic, Charlotte

33136

Jackson Memorial Hospital, Miami

35233

Children's Hospital of Alabama, Birmingham

37232

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville

40536

University of Kentucky, Lexington

44308

Akron Children's Hospital, Akron

49202

Schneider Children Medical Center of Israel, Petah Tikva

63141

Mercy Clinic Children's Cancer and Hematology Center, St Louis

73104

The Children's Hospital at Oklahoma University Medical Center, Oklahoma City

75235

Children's Medical Center of Dallas, Dallas

80045

Children's Hospital Colorado, Aurora

90723

Bayview Research Group, LLC, Paramount

All Listed Sponsors
lead

Purdue Pharma LP

INDUSTRY

NCT01369615 - Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001 | Biotech Hunter | Biotech Hunter